Parkinson’s Disease Market: Accelerating Growth and Pipeline Impact by 2036 – DelveInsight | Roche, Amneal Pharma, AbbVie, Supernus Pharma, Britannia Pharma, AbbVie, Cerevel Therapeutics, Pharma Two

The Key Parkinson’s Disease Companies in the market include - Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others.

 

(Albany, New York) - November 04, 2026: DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Parkinson’s Disease, historical and forecasted epidemiology as well as the Parkinson’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Parkinson’s Disease, offering comprehensive insights into the Parkinson’s Disease revenue trends, prevalence, and treatment landscape. The report delves into key Parkinson’s Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Parkinson’s Disease therapies. Additionally, we cover the landscape of Parkinson’s Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Parkinson’s Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Parkinson’s Disease space.

 

Get a Free sample for the Parkinson’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment

 

Some of the key facts of the Parkinson’s Disease Market Report:

• The Parkinson’s Disease market size was valued at approximately USD 3,539 million in 2025 and is expected to experience substantial growth at a notable CAGR between 2024 and 2036.

• The Parkinson's Disease Therapeutics Market Size in the US was ~USD 1,883 million in 2023, which is anticipated to increase due to the increasing awareness of the disease and the launch of the emerging therapy. The Parkinson's Disease Market Size of EU4 and the UK was calculated to be ~USD 988 million in 2023, which was nearly 31% of the total market revenue for the 7MM.

• In October 2026, Cerevance reported positive topline findings from its Phase III ARISE trial assessing solengepras as an add-on therapy for patients with Parkinson’s disease who experience motor fluctuations despite receiving standard levodopa treatment. The 150 mg dose met the primary endpoint, showing a statistically significant reduction of 0.61 hours in daily OFF time compared with placebo at Week 12. Additionally, the treatment demonstrated improvements in ON time without troublesome dyskinesia and motor experiences of daily living. Cerevance intends to engage with the FDA to discuss the findings and determine the potential regulatory pathway for filing a New Drug Application (NDA).

• In October 2026, Arvinas presented further Phase I clinical data for ARV-102, an investigational PROTAC-based LRRK2 degrader being developed as a potential treatment for Parkinson’s disease. The study, which included 24 patients, demonstrated dose-dependent improvements in saccadic hypometria, along with changes in cerebrospinal fluid biomarkers linked to endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance. These findings provide further support for investigating LRRK2 degradation as a promising therapeutic strategy for neurodegenerative disorders.

• In Oct 2026, Lundbeck presented positive Phase Ib clinical data for Lu AF28996 in patients with advanced Parkinson's disease while announcing the simultaneous initiation of a broader Phase II clinical trial. The data highlight the drug's favorable safety profile and pharmacokinetic properties in managing motor complications and fluctuations associated with advanced disease stages. The advancement into Phase II underscores Lundbeck's ongoing commitment to expanding innovative therapeutic options and improving quality of life for neurodegenerative disease patients.

• In September 2026, According to regulatory listings from the US FDA, AbbVie has secured approval for Juvmo (tavapadon), a daily oral therapy for adults with Parkinson's disease. The pharmaceutical company added the drug to its portfolio through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.

• In September 2026, Hopledo (IPX203), an extended-release combination of levodopa and carbidopa marketed as Crexont in the U.S., has received European Union approval for adults with Parkinson’s disease who experience motor fluctuations despite ongoing treatment. The European Commission’s decision was largely supported by clinical trial data demonstrating that Hopledo significantly increased good “on” time, when Parkinson’s symptoms are adequately controlled, compared with immediate-release formulations. The extended-release therapy also offered the benefit of requiring fewer doses per day.

• In August 2026, The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XS411, an off-the-shelf stem cell therapy developed by China-based Xellsmart for Parkinson’s disease. The investigational treatment is designed to replace dopamine-producing nerve cells lost during disease progression and potentially restore neurological function. Fast Track status may facilitate more efficient regulatory interactions and expedite development and review if clinical results demonstrate meaningful benefits. Clinical trials of XS411 have already received authorization in both China and the United States.

• In June 2026, Gain Therapeutics has secured FDA clearance for its Investigational New Drug (IND) application, enabling the initiation of a Phase II clinical trial evaluating GT-02287, an oral glucocerebrosidase (GCase) activator, as a potential treatment for Parkinson's disease.

• In May 2026, The Phase IIb PADOVA trial investigating prasinezumab, an anti-alpha-synuclein monoclonal antibody, released efficacy and safety findings in patients with early-stage Parkinson’s disease, supporting ongoing efforts to develop disease-modifying therapies for the condition.

• In May 2026, The Phase III TEMPO-3 trial delivered positive results for tavapadon as an adjunctive therapy in Parkinson’s disease, highlighting its potential as a novel dopamine receptor agonist for improving disease management.

• In March 2026, Oryon Cell Therapies has announced updated clinical and neuroimaging findings from its ongoing Phase 1b/2a trial assessing an autologous dopaminergic neuron replacement therapy for Parkinson's disease. The company is focused on developing autologous neuron-based treatments for Parkinson’s and other neurodegenerative conditions. The study is being carried out in collaboration with experts from Mass General Brigham, led by the Neuroregeneration Institute at McLean Hospital. Participants in the trial received unilateral neuronal implants. Preliminary results indicate improvements in motor function, along with neuroimaging evidence suggesting restoration of dopaminergic signaling in the transplanted region of the brain.

• In January 2026, The U.S. Food and Drug Administration (FDA) has approved a new treatment option for individuals with advanced Parkinson’s disease (PD). Known as Vyalev, the therapy administers two established Parkinson’s medications through a continuous subcutaneous infusion, providing a steady and less invasive method of treatment. This innovative approach is designed to help patients achieve improved and longer-lasting control of movement symptoms associated with advanced PD.

• This expansion is primarily fueled by improvements in diagnostic technologies, growing awareness of Parkinson’s disease, and an increasing prevalence of reported cases.

• The U.S. The Parkinson's Disease market was valued at around USD 1,883 million in 2023 and is expected to grow further, driven by rising disease awareness and the introduction of emerging therapies.

• In 2023, the combined Parkinson’s Disease market size for the EU4 and the UK was estimated at around USD 988 million, accounting for approximately 31% of the total 7MM market revenue.

• In January 2026, Two innovative therapies are approaching the final stages of clinical development ahead of potential FDA approval. One is a novel dopamine-based treatment targeting motor symptom management, while the other is a stem cell therapy aimed at replacing lost brain cells in Parkinson’s disease (PD). These approaches offer distinct yet complementary strategies in addressing PD. Additionally, AbbVie has announced the submission of a new drug application (NDA) to the US FDA for tavapadon, a once-daily oral therapy intended to alleviate PD symptoms, including stiffness, tremors, and slowed movement.

• In June 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced its decision to advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease. This move is based on findings from the Phase IIb PADOVA study and ongoing open-label extension (OLE) studies from both PADOVA and the earlier Phase II PASADENA trial.

• In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.

• In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.

• In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.

• DelveInsight’s epidemiology model estimates that the total diagnosed prevalent cases of Parkinson’s disease in the US were around 1.21 million in 2023, with numbers expected to rise over the forecast period (2024–2036) driven by greater disease awareness, an aging population, and improvements in diagnostic methods.

• In 2023, Japan represented around 258,000 diagnosed prevalent cases of Parkinson’s disease within the 7 major markets (7MM).

• In 2023, within the EU4 and the UK, Germany recorded the highest number of diagnosed Parkinson’s disease cases at around 495,000, followed by France with approximately 277,000 cases, while Spain reported the lowest at nearly 149,000 cases.

• In 2023, Japan reported around 135,000 male and 123,000 female cases of Parkinson’s disease based on gender-specific diagnosed prevalence, with numbers projected to rise over the forecast period.

• In 2023, the United States recorded approximately 19,000 Parkinson’s disease cases in individuals aged ≤49 years, 215,000 cases in the 50–64 age group, 449,000 cases in those 65–74 years, and 527,000 cases in people aged ≥75 years.

• In 2023, Japan’s stage-specific diagnosed prevalent Parkinson’s disease cases were approximately 9,000 for Stage I, 40,000 for Stage II, 107,000 for Stage III, 70,000 for Stage IV, and 31,000 for Stage V.

• In 2023, Japan recorded around 73,000 cases of Parkinson’s disease-related psychosis.

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), SPN-830 (apomorphine infusion device), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• The Parkinson’s Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson’s Disease pipeline products will significantly revolutionize the Parkinson’s Disease market dynamics.

 

Parkinson’s Disease Overview

Parkinson’s Disease (PD) is a chronic, progressive neurological disorder that primarily affects movement. It occurs due to the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra region. Common symptoms include tremors, rigidity, slowed movement (bradykinesia), balance difficulties, and postural instability. Non-motor symptoms, such as sleep disturbances, depression, cognitive impairment, and autonomic dysfunction, are also common. While there is no cure, treatments including medications (like levodopa), deep brain stimulation, and lifestyle interventions aim to manage symptoms, improve quality of life, and slow disease progression. Early diagnosis is key for effective management.

 

To Know in detail about the Parkinson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson’s Disease Market Forecast

 

Parkinson’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Parkinson’s Disease Epidemiology Segmentation:

The Parkinson’s Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Parkinson’s Disease

• Prevalent Cases of Parkinson’s Disease by severity

• Gender-specific Prevalence of Parkinson’s Disease

• Diagnosed Cases of Episodic and Chronic Parkinson’s Disease

 

Download the report to understand which factors are driving Parkinson’s Disease epidemiology trends @ Parkinson’s Disease Epidemiology Forecast

 

Parkinson’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease market or expected to get launched during the study period. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parkinson’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Parkinson’s Disease Therapies and Key Companies

• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals

• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie

• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals

• Tavapadon: AbbVie (Cerevel Therapeutics)

• P2B001 (extended-release pramipexole and rasagiline): Pharma Two B

• KM-819: FAScinate Therapeutics

• Prasinezumab: Hoffmann-La Roche

• P2B001: Pharma Two B Ltd.

• NPT1220-478: Neuropore Therapies, Inc.

• Dapansutrile: Olatec Therapeutics

• UCB7853: UCB Biopharma

• UB-312: Vaxxinity

• Emrusolmin: Modag

• PT320: Peptron

• KDT-3594: Kissei Pharmaceutical

• Tavapadon: Cerevel Therapeutics

 

Discover more about therapies set to grab major Parkinson’s Disease market share @ Parkinson’s Disease Treatment Landscape

 

Parkinson’s Disease Market Drivers

• Rising Prevalence: Increasing number of Parkinson’s disease cases globally due to aging populations.

• Growing Awareness: Enhanced awareness among patients and physicians leading to earlier diagnosis and treatment.

• Advancements in Therapies: Introduction of innovative treatments, including dopamine agonists, MAO-B inhibitors, gene therapies, and device-based therapies.

• Expanding Pipeline: Continuous R&D and clinical trials for novel disease-modifying therapies.

• Favorable Reimbursement & Healthcare Access: Improved insurance coverage and government initiatives supporting neurological care.

 

Parkinson’s Disease Market Barriers

• High Treatment Costs: Expensive therapies and device-based interventions limit patient access.

• Side Effects & Safety Concerns: Long-term use of medications may cause complications like dyskinesia and cardiovascular issues.

• Lack of Curative Therapies: Current treatments mainly manage symptoms rather than halt disease progression.

• Complex Diagnosis: Delayed or misdiagnosis due to overlapping symptoms with other neurological disorders.

• Market Fragmentation: Variation in healthcare infrastructure and reimbursement policies across regions.

 

Scope of the Parkinson’s Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), SPN-830 (apomorphine infusion device), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Parkinson’s Disease Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Market Access and Reimbursement

 

To know more about Parkinson’s Disease companies working in the treatment market, visit @ Parkinson’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Parkinson’s Disease Market Report Introduction

2. Executive Summary for Parkinson’s Disease

3. SWOT analysis of Parkinson’s Disease

4. Parkinson’s Disease Patient Share (%) Overview at a Glance

5. Parkinson’s Disease Market Overview at a Glance

6. Parkinson’s Disease Disease Background and Overview

7. Parkinson’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Parkinson’s Disease

9. Parkinson’s Disease Current Treatment and Medical Practices

10. Parkinson’s Disease Unmet Needs

11. Parkinson’s Disease Emerging Therapies

12. Parkinson’s Disease Market Outlook

13. Country-Wise Parkinson’s Disease Market Analysis (2022–2036)

14. Parkinson’s Disease Market Access and Reimbursement of Therapies

15. Parkinson’s Disease Market Drivers

16. Parkinson’s Disease Market Barriers

17. Parkinson’s Disease Appendix

18. Parkinson’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Metro Cellar Door Bilco Pro Shares FHFA Data on a Year of 5.7 Percent Home Value Growth in the New York Area

Following a 5.7 percent annual gain in FHFA's New York-Jersey City-White Plains index, Metro Cellar Door Bilco Pro explains how its installers replace worn sidewalk, Bilco and bulkhead doors.

NEW YORK, NY - November 4, 2026 - Metro Cellar Door Bilco Pro, a cellar door installer that replaces sidewalk cellar doors and Bilco doors on residential and commercial properties in New York City, is sharing Federal Housing Finance Agency (FHFA) house price data for the area, along with guidance for owners with a rusted, loose or leaking cellar door.

The FHFA's all-transactions House Price Index for the New York-Jersey City-White Plains metropolitan division tracks average price changes in repeat sales and refinancings of the same single-family properties.

Area House Prices Through Mid-2026

The FHFA index for the area climbed to 454.16 in the second quarter of 2026, from 429.58 a year earlier, a gain of about 5.7 percent. Readings rose through the year, from 436.06 at the end of 2025 to 441.94 in the first three months of 2026.

The index follows home values over time. It does not measure the condition of any building's entrances or basement doors.

Why Sidewalk Cellar Doors Wear Out

Between foot traffic, water exposure and New York winters, sidewalk doors eventually rust, loosen or become unsafe. When that happens, the company can recommend a replacement door or build a custom cellar door if the opening calls for one, then install a flat cellar door or bulkhead door that sits securely and flush with the sidewalk.

Bulkhead Doors Versus Basement Doors

A bulkhead door usually means an angled exterior door leading to a basement, often mounted over concrete steps or a sloped foundation. These are common on older homes and are sometimes called Bilco doors. A basement door can mean any entry to the basement, including interior doors, exterior doors or egress windows with doors. The company installs both, depending on the layout.

Choosing a Material

For keeping a basement entry dry and secure, the company recommends steel or galvanized steel, which resist rust and last longer in New York City weather than wood, which can warp or rot. Some owners choose powder-coated steel for extra protection. The company also installs moulding, weatherproof seals and custom flashing. The door type, added width, a sloped foundation or uneven concrete, and any foundation or framing repairs can all change the scope of a job.

Metro Cellar Door Bilco Pro's Work in New York City

The replacement process has three steps: the owner schedules an appointment, a team visits to take measurements and discuss options, and once the details are final the door is ordered and an installation date is set. Its installers work on brownstones, rowhouses, townhomes and two-family houses, as well as apartment buildings, storefronts and warehouses, and contractors can work with the company too. Its website says it offers direct-from-manufacturer pricing and lists Queens, Brooklyn, the Bronx and Staten Island among the areas it serves.

About Metro Cellar Door Bilco Pro

Metro Cellar Door Bilco Pro is a cellar door installer in New York City that installs and replaces sidewalk cellar doors, Bilco and bulkhead doors, and fire-rated doors.

Media Contact

Metro Cellar Door Bilco Pro

New York City, NY

(929) 979-7313

https://metrocellardoor.com/

Sources: Federal Housing Finance Agency, House Price Index, all-transactions index by metro area (quarterly): https://www.fhfa.gov/hpi/download/quarterly_datasets/hpi_at_metro.csv ; FHFA HPI datasets page: https://www.fhfa.gov/data/hpi/datasets

Media Contact
Company Name: Metro Cellar Door Bilco Pro
Contact Person: Christopher Long
Email:Send Email
Phone: 929-979-7313
City: New York
State: NY
Country: United States
Website: https://metrocellardoor.com

Clean Slate Hauling And Junk Removal Shares Census Count of 630 New Lacey Housing Units Authorized in 2025

Clean Slate Hauling And Junk Removal has published a guide that pairs U.S. Census Bureau building permit counts for Lacey with how its Lacey crew handles cleanouts, light demolition and construction debris.

LACEY, WA - November 4, 2026 - Clean Slate Hauling And Junk Removal Lacey, a junk removal service for Lacey and the surrounding Thurston County area, is sharing U.S. Census Bureau building permit data for the city, along with guidance for homeowners, landlords and contractors planning a cleanout or remodel.

Every number below is from the Census Bureau's Building Permits Survey, which compiles the new homes and apartments that local permit offices approve each year. This release compares Lacey's 2024 and 2025 annual entries.

New Housing Units Authorized in Lacey

Lacey's permit office approved 630 new housing units in 2025, the survey shows, and most of them were in larger buildings: 602 units in 16 buildings with five or more units, along with 26 single-family homes and 2 units in a duplex.

In 2024, the city authorized 178 new housing units, including 137 units in buildings with five or more units and 37 single-family homes. The 2025 total was more than three times the 2024 figure.

Permit counts measure authorized new construction. They do not count remodels, move-outs or cleanouts in existing homes.

How Estimates and Pricing Work

Clean Slate gives junk removal quotes based on the type and volume of items being removed, and the price is given before any work begins. The company can do a quick on-site review when a job is hard to describe over the phone. For larger jobs, such as a full cleanout of a three-bedroom house, it says pricing depends on volume, access and the kinds of items involved rather than square footage.

Soft Strip, Light Demolition and Debris

People planning a remodel often ask about demolition. Clean Slate explains that a soft strip removes non-structural items such as cabinets, fixtures, flooring and interior materials, while total demolition removes the whole structure. The company's work centers on soft strip and light demolition, such as taking down sheds, decks and small interior structures, followed by hauling. It does not do full building teardowns. Construction debris removal covers wood, drywall, flooring and other materials left after remodeling or repairs.

Clean Slate's Work in Lacey

The company describes its Thurston County work as full-service junk removal. Residential jobs cover old furniture, broken appliances, mattresses and general clutter from houses, apartments and condos. Garage cleanouts cover packed storage, tools, shelving and yard equipment. Property cleanouts help landlords and estate representatives clear rentals, estates and foreclosed homes, and the company offers no-judgment hoarder cleanouts with attention to privacy. On the commercial side, it handles office furniture, storage cleanouts and ongoing pickup for offices, retail spaces and property managers.

Clean Slate sorts loads when it can, separates reusable materials and uses approved facilities for disposal. Its website lists its Lacey service as open 24 hours a day, seven days a week, and it has pages for Lacey, Tumwater, Yelm and North Olympia.

About Clean Slate Hauling And Junk Removal

Clean Slate Hauling And Junk Removal is a junk removal and hauling company in Washington State. From Lacey, its crew covers Tumwater, Yelm and North Olympia with junk removal, cleanouts, light demolition and debris hauling.

Media Contact

Clean Slate Hauling And Junk Removal Lacey

Olympia, WA

(360) 227-8738

https://cleanslatejunk.net/lacey-junk-removal/

Sources: U.S. Census Bureau, Building Permits Survey, annual place data, West Region, 2025: https://www2.census.gov/econ/bps/Place/West%20Region/we2025a.txt ; 2024: https://www2.census.gov/econ/bps/Place/West%20Region/we2024a.txt

Media Contact
Company Name: Clean Slate Hauling And Junk Removal Lacey
Contact Person: Josh Williamson
Email:Send Email
Phone: (360) 227-8738
Address:400 Union Ave SE Suite 209
City: Olympia
State: WA
Country: United States
Website: https://cleanslatejunk.net/lacey/

Charleston Healthspan Shares 2025 Census Bureau Population Estimates for Berkeley County

Charleston Healthspan - Hormones & Peptides has published a guide that pairs the latest U.S. Census Bureau population estimates for Berkeley County with how its Daniel Island practice approaches a first hormone therapy visit.

DANIEL ISLAND, SC - November 4, 2026 - Charleston Healthspan - Hormones & Peptides, a Daniel Island practice that provides hormone therapy for men and women in the Charleston area, is sharing U.S. Census Bureau population estimates for Berkeley County, along with information on how its consultation, services and payment process work.

The guide draws on the Census Bureau's Vintage 2025 population estimates for Berkeley County, which includes Daniel Island.

Berkeley County Population Estimates

Berkeley County's estimated population reached 274,666 on July 1, 2025, a 19.5 percent increase over the April 2020 estimates base of 229,779, the Census Bureau reports. The county had an estimated 110,241 housing units in 2025, and the Census Bureau reports 2,299 building permits for the year.

Residents age 65 and older made up 16.2 percent of the county's population, and those under 18 made up 22.9 percent.

These estimates describe the county's population. They do not say anything about the health needs of any one person.

How a First Visit Works

According to the practice, timing and treatment depend on each patient's symptoms, medical history and lab results. A hormone evaluation comes first, and any plan is built around the individual patient's goals. The website lists symptoms that lead people to ask about therapy, including mood changes, fatigue, low energy and loss of muscle mass. Whether a given treatment is appropriate is a decision made with the provider after an evaluation.

Patients do not have to sign up for a monthly program or annual contract. The practice says it sets each patient's regimen individually.

Payment and Insurance

Charleston Healthspan is an out-of-network provider and does not accept insurance payments for its services. It gives patients a statement listing services with diagnosis, laboratory and procedure codes, which patients can submit to their insurer for possible reimbursement or toward a deductible or flexible spending account. The practice has opted out of Medicare, so patients with Medicare cannot file claims for services there. It does not publish prices and says costs vary by treatment.

Charleston Healthspan's Work in the Charleston Area

The practice's services menu includes bio-identical hormone replacement therapy, including pellet therapy; menopause and andropause care; sexual health care; peptide therapy; GLP-1 therapy and medically supervised weight loss; PRP hair restoration; and postpartum hormone support. The practice states that it uses only bio-identical hormones. Its website names Dr. Susan Kady Wilson as its physician and says she has more than 27 years of experience in hormone replacement therapy.

The main office is at 125 River Landing Dr on Daniel Island, and the website lists additional offices in Summerville and Georgetown.

About Charleston Healthspan - Hormones & Peptides

Charleston Healthspan - Hormones & Peptides is a hormone therapy and wellness practice based on Daniel Island in South Carolina, serving men and women in the Charleston area. The information in this release is general and is not medical advice.

Media Contact

Charleston Healthspan - Hormones & Peptides

125 River Landing Dr, Suite 101, Daniel Island, SC 29492

(843) 375-6588

https://charlestonhealthspan.com/

Sources: U.S. Census Bureau, QuickFacts, Berkeley County, South Carolina (Vintage 2025): https://www.census.gov/quickfacts/berkeleycountysouthcarolina

Media Contact
Company Name: Charleston Healthspan Institute
Contact Person: Dr. Susan K Wilson
Email:Send Email
Phone: 843-375-6588
Address:125 River Landing Dr #101
City: Daniel Island
State: SC 29492
Country: United States
Website: https://charlestonhealthspan.com

AZ Cabinets Shares 2025 Census Population and Housing Data for Phoenix Homeowners Planning Kitchen Cabinets

AZ Cabinets has published a guide that pairs U.S. Census Bureau figures for Phoenix with what its Indian School Road showroom says about choosing, ordering and receiving new cabinets.

PHOENIX, AZ - November 4, 2026 - AZ Cabinets, a cabinet store that sells kitchen and bathroom cabinets to Phoenix homeowners from its showroom at 3301 E Indian School Rd, is sharing U.S. Census Bureau population and housing data for Phoenix alongside guidance on how a cabinet order works, from the first showroom visit to delivery.

The guide draws on the Census Bureau's QuickFacts profile for Phoenix, which combines the Vintage 2025 population estimates with American Community Survey (ACS) 5-year figures for 2020 to 2024.

Phoenix Population and Households

The Census Bureau estimates Phoenix had 1,665,481 residents on July 1, 2025, up 3.6 percent from the April 2020 estimates base of 1,608,349. The ACS counts 610,442 households in the city for 2020 to 2024, with an average of 2.65 people per household.

Phoenix Housing Figures

According to the same profile, 57.3 percent of occupied Phoenix housing units were owner occupied in the 2020 to 2024 period. The median value of an owner-occupied home was $420,700, and median monthly owner costs for homes with a mortgage were $1,847. Median gross rent was $1,582.

Those figures describe the city as a whole. They do not show what any one household spends on a kitchen, and project costs depend on the layout, materials and finishes chosen.

How a Cabinet Order Works

AZ Cabinets describes its process in a few steps. Buying starts in the showroom, where customers look at the selection. They then choose a cabinet style, material and finish, and the AZ Cabinets team takes measurements and prepares a quote. The team can also help plan a layout, whether a homeowner is remodeling an existing kitchen or designing a new one.

The store states that cabinet delivery typically takes two to four weeks after ordering. AZ Cabinets does not install cabinets. It recommends local contractors who do, and handy homeowners can install the cabinets themselves, so the company suggests confirming delivery timing before setting an installation date.

AZ Cabinets' Work in Phoenix

The showroom carries contemporary, traditional, European-style and shaker-style cabinetry. Its semi-custom kitchen cabinets come in materials including plywood, glass, wood, MDF and particle board, and kitchen and bathroom finishes include wood veneers and laminates. Cabinet doors come in solid wood, metal, glass, laminate and plywood, in raised panel, flat panel, shaker and slab styles, and the store stocks hinges, drawer pulls and moldings.

The company also sells wholesale cabinets for homeowners, contractors and designers, and cabinets for offices and entertainment areas. Its website lists Camelback East Village, Central City, Deer Valley, Midtown and Paradise Valley Village among the Phoenix urban villages it serves, and it calls its Indian School Road location its Arcadia showroom. Shipping and delivery are available for all of its products, and warranty coverage varies by product line.

About AZ Cabinets

AZ Cabinets is a cabinet store in Phoenix, Arizona, selling kitchen cabinets, bathroom cabinets, cabinet doors and wholesale cabinets to homeowners, contractors and designers.

Media Contact

AZ Cabinets

3301 E Indian School Rd Ste 103, Phoenix, AZ 85018

(602) 314-6238

https://azcabinetcompany.com/

Sources: U.S. Census Bureau, QuickFacts, Phoenix city, Arizona (Vintage 2025 estimates; ACS 2020-2024): https://www.census.gov/quickfacts/fact/table/phoenixcityarizona/PST045225

Media Contact
Company Name: Cabinets 4 Less – AZ Cabinets
Contact Person: Chris Montoya
Email:Send Email
Phone: (602) 314-6238
Address:3301 E Indian School Rd, Suite 103
City: Phoenix
State: AZ 85018
Country: United States
Website: https://azcabinetcompany.com

Discovery Point Retreat Reports 43% Drop in Client Distress Across Its Full Continuum of Addiction Care

Discovery Point Retreat November 2026 clinical outcomes report

A year of weekly outcomes data from more than 500 adults who moved from residential care into outpatient treatment shows broad gains in depression, anxiety, trauma symptoms and substance use severity.

Dallas, Texas - November 04, 2026 - Discovery Point Retreat (DPR) today released a new year of clinical outcomes data covering October 2025 through October 2026. The data tracks adults in treatment for substance use disorders at DPR's residential facilities in Ennis and Waxahachie and its outpatient center in Dallas. The findings were collected by Discovery Point Retreat, LLC, verified by Discovery MSO, LLC, and prepared for clinical review by Lauren Reisman, LMSW, and Dr. Jerry Vaccaro, M.D.

The headline result comes from 528 adults who received care at both levels: residential treatment at Ennis or Waxahachie, followed by partial hospitalization (PHP) or intensive outpatient (IOP) care in Dallas. From residential admission to outpatient discharge, overall symptom distress fell 43%, and 80.5% of these clients showed improvement.

Every clinical area in the report improved. Across the full continuum, depressive symptoms dropped 49%, anxiety symptoms dropped 38%, and trauma-related distress dropped 40%. Substance use severity, which combines use, cravings and the consequences of use, fell 58%, with 81.6% of clients improving. Relationship functioning improved 30%. Of the clients who arrived with clinically elevated depression, 72.3% scored below the clinical threshold by their last outpatient survey. Clients also rated their care highly, with 95% satisfaction with their treatment experience and their relationship with their care team.

DPR tracks progress with a weekly self-report survey that every program uses. Its questions are aligned with widely used clinical screening tools such as the PHQ-9 for depression and the GAD-7 for anxiety. Because the same survey runs from detox through IOP, the care team can follow each client's progress across levels of care instead of starting over at each step.

Those results compare well against national benchmarks. DPR's survey is modeled on a widely used outcome scale whose developers consider a 10-point drop in symptom distress to be a reliable, meaningful change. Clients who received care across DPR's continuum averaged a 20-point drop. Among those continuum clients who arrived with elevated depression, 67% saw their depression scores fall by half or more, compared with 46% in a national study of 5,554 psychotherapy episodes. DPR is accredited by The Joint Commission, and this year's results draw on 1,886 clients and nearly 10,000 weekly surveys.

Results at each facility also held up on their own. At Ennis, where 740 adults had paired surveys, overall distress fell 35% and 77.7% of clients improved. At Waxahachie, DPR's private-room residential facility, 217 adults saw overall distress fall 31% and substance use severity fall 42%. Both facilities run the same clinical model, with detox followed by residential care that typically lasts four to five weeks.

In Dallas, where clients arrive already stabilized after residential care, the focus shifts to holding those gains while people return to work, family and daily life. Among 739 outpatient clients, substance use severity fell another 26%, and problems at work, school and home tied to use dropped 38%. Peer-group acceptance and participation in a sober lifestyle rose 22%. In the outpatient program, 96% of clients rated their treatment experience and their relationship with their care team highly.

"These numbers come from clients telling us every week how they're doing, so we can see what's working and adjust while someone is still in our care. The biggest takeaway is what happens when people stay connected through the whole continuum. Residential care helps someone stabilize, and outpatient care helps them build on that progress. Our strongest results come from clients who stay with us through both levels of care." — Michael Banis, Chief Growth Officer, Discovery MSO

The outcomes reflect self-reported symptom severity and day-to-day functioning. They are not sobriety or relapse rates.

Adults in Texas looking for detox, residential or outpatient treatment can call Discovery Point Retreat at (855) 635-4776 or contact the admissions team online.

About Discovery Point Retreat

Discovery Point Retreat is a Texas-based addiction treatment provider offering medical detox, residential treatment, partial hospitalization and intensive outpatient care for adults. With residential facilities in Ennis and Waxahachie and an outpatient center in Dallas, DPR provides a full continuum of care for substance use disorders and co-occurring mental health conditions.

Media Contact
Company Name: Discovery Point Retreat
Contact Person: Michael Banis
Email:Send Email
Phone: (855) 635-4776
Address:4306 Capitol Ave
City: Dallas
State: Texas
Country: United States
Website: https://discoverypointretreat.com

Metastatic Melanoma Pipeline Update 2026: Clinical Development Status, Collaborations, and Key Companies to Watch | Evaxion Biotech, InxMed, AiVita Biomedical, Apexigen, Checkmate Pharma, Nektar

(Albany, New York) - November 04, 2026: As per DelveInsight’s assessment, globally, Metastatic Melanoma pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Metastatic Melanoma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

 

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Metastatic Melanoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years.

• Metastatic Melanoma companies working in the treatment market are Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others, are developing therapies for the Metastatic Melanoma treatment

• Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.

• In October 2026, Faron Pharmaceuticals announced that the final overall survival results from the metastatic melanoma cohort of its Phase I/II MATINS study (NCT03733990) had been accepted for presentation at ESMO 2026. The trial investigated bexmarilimab, an investigational macrophage checkpoint inhibitor, as a monotherapy in 25 patients with metastatic melanoma who had developed resistance to checkpoint inhibitor therapy. The results are expected to provide further clinical support for the ongoing Phase I/II BLAZE trial, which is assessing bexmarilimab in combination with nivolumab in patients with metastatic melanoma and non-small cell lung cancer (NSCLC) who have progressed following anti-PD-1 treatment. The first patient in the BLAZE trial received treatment on October 1, 2026.

• In August 2026, The U.S. FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg), an investigational genetically engineered oncolytic viral therapy, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with a PD-1-blocking antibody-based regimen. The approval was based on clinical findings showing an objective response rate of 24% among evaluable patients, with a median duration of response of 14.1 months. The therapy is designed to selectively target and destroy cancer cells while activating an antitumor immune response. Continued approval is contingent upon confirmatory clinical evidence from the Phase III IGNYTE-3 trial.

• In July 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 in favour of the clinical efficacy evidence supporting RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma who experienced disease progression following anti-PD-1 therapy. The committee considered evidence from the IGNYTE clinical trial, including durable responses in heavily pretreated patients. This regulatory milestone preceded the FDA's accelerated approval of the combination in August 2026.

• In July 2026, clinical trial findings reported for advanced melanoma indicated that the combination of tucidinostat, an HDAC inhibitor, and nivolumab, an anti-PD-1 immunotherapy, improved progression-free survival compared with nivolumab alone in previously untreated advanced melanoma patients. The findings highlight the potential of combining epigenetic modulation with immune checkpoint inhibition to enhance antitumor activity. The combination remains investigational and requires further clinical evaluation.

• In June 2026, the US FDA accepted Replimune's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec), an investigational oncolytic immunotherapy, in combination with nivolumab for patients with advanced melanoma. The application was classified as a complete Class 1 response, with an FDA action date of August 2, 2026. The therapy is designed to selectively target tumor cells and stimulate antitumor immunity. The regulatory development followed two previous complete response letters and was supported by clinical findings from the IGNYTE study.

• In May 2025, Immatics announced the presentation of updated data from its ongoing Phase Ib trial assessing IMA203 in heavily pretreated metastatic melanoma patients. The company also shared information from a trial-in-progress poster on SUPRAME, the Phase III study evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have previously received checkpoint inhibitor therapy, at ASCO 2025.

 

Metastatic Melanoma Overview

Metastatic Melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells spread beyond the original tumor site to distant organs such as the lungs, liver, brain, or bones. It occurs when melanoma cells invade the bloodstream or lymphatic system, leading to secondary tumors. Metastatic melanoma is highly aggressive but can be treated with targeted therapies (BRAF and MEK inhibitors), immunotherapy (checkpoint inhibitors like nivolumab and pembrolizumab), chemotherapy, or radiation therapy. Early detection and advanced treatments have improved survival rates and patient outcomes.

 

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight

 

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:

• IMA203: Immatics Biotechnologies

• RP1 (vusolimogene oderparepvec) plus nivolumab: Replimune and Bristol Myers Squibb

• Nidlegy: Philogen

• TILT 123: TILT Biotherapeutics

• AV-MEL-1: AiVita Biomedical

• IMM-1-104: Immuneering Corporation

• UV1: Ultimovacs ASA

• APX005: MPyxis Oncology

• EVX 01: Evaxion Biotech

• HBI-8000: HUYABIO International, LLC.

• IO102-IO103: IO Biotech

• Fianlimab: Regeneron Pharmaceuticals

 

Metastatic Melanoma Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

 

Metastatic Melanoma Molecule Type

Metastatic Melanoma Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

 

Metastatic Melanoma Pipeline Therapeutics Assessment

• Metastatic Melanoma Assessment by Product Type

• Metastatic Melanoma By Stage and Product Type

• Metastatic Melanoma Assessment by Route of Administration

• Metastatic Melanoma By Stage and Route of Administration

• Metastatic Melanoma Assessment by Molecule Type

• Metastatic Melanoma by Stage and Molecule Type

 

DelveInsight's Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies

 

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:

Key companies developing therapies for Metastatic Melanoma are - Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.

 

Metastatic Melanoma Pipeline Analysis:

The Metastatic Melanoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.

• Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies

 

Metastatic Melanoma Pipeline Market Drivers

• Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

 

Metastatic Melanoma Pipeline Market Barriers

• However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

 

Scope of Metastatic Melanoma Pipeline Drug Insight

• Coverage: Global

• Key Metastatic Melanoma Companies: Immatics Biotechnologies, Replimune and Bristol Myers Squibb, Philogen, TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others

• Key Metastatic Melanoma Therapies: IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, Nidlegy, TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others

• Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies

• Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers

 

Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Metastatic Melanoma Report Introduction

2. Metastatic Melanoma Executive Summary

3. Metastatic Melanoma Overview

4. Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Melanoma Pipeline Therapeutics

6. Metastatic Melanoma Late Stage Products (Phase II/III)

7. Metastatic Melanoma Mid Stage Products (Phase II)

8. Metastatic Melanoma Early Stage Products (Phase I)

9. Metastatic Melanoma Preclinical Stage Products

10. Metastatic Melanoma Therapeutics Assessment

11. Metastatic Melanoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Melanoma Key Companies

14. Metastatic Melanoma Key Products

15. Metastatic Melanoma Unmet Needs

16 . Metastatic Melanoma Market Drivers and Barriers

17. Metastatic Melanoma Future Perspectives and Conclusion

18. Metastatic Melanoma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

XIAOPAI Highlights Solventless Laminating Machine Purchasing Options and Factory Support

Wenzhou Xiaopai Electric Power Technology Co., Ltd.

XIAOPAI highlights solventless laminating machine options and purchasing support for flexible packaging buyers. As an authorized global distributor of SINSTAR, it coordinates model selection, export documentation, commissioning and after-sales services. The TRI-1300A supports three-layer lamination with a maximum rated speed of 450 m/min and a maximum laminating width of 1,350 mm.

WENZHOU, China - November 3, 2026 - XIAOPAI is a China-based solventless laminating machine supplier and an authorized global distributor of SINSTAR. With technical updates published on November 2 covering automated lamination and three-layer processing, the company is highlighting equipment specifications and factory support available to overseas packaging converters. Its solventless laminating machine offering brings together model selection, export documentation and coordination with SINSTAR engineers. The purchasing focus is practical: selecting equipment for the required laminate and establishing the support arrangements needed to move from quotation to production.

Equipment Specifications for Three Layer Packaging

The TRI-1300A triplex model provides a specific reference for buyers assessing the XIAOPAI solventless laminating machine range. It is designed to laminate three layers in one process and is listed for structures including PET/AL/PE and BOPP/CPP/PE. Applications include food packaging, pharmaceutical laminates and personal care packaging.

• Maximum laminating speed: 450 m/min.

• Maximum laminating width: 1,350 mm.

• Maximum unwinding diameter: 800 mm.

• Maximum rewinding diameter: 800 mm.

• Material loading: Shaftless loading.

• Compatible core sizes: 3 inches and 6 inches.

• Listed laminate structures: PET/AL/PE and BOPP/CPP/PE.

Listed controls include digital adhesive-volume settings, digital tension control and a three-roll back-pressure laminating mechanism. Buyers can use these specifications as reference points when comparing machine configurations.

For buyers assessing a Roll to Roll Laminating Machine, the required bonding process and layer structure guide the choice of configuration. Rated maximum speed is a comparison point; application-specific operating conditions and laminate quality remain subject to the agreed material trial.

November Technical Updates Address Automation and Repeat Orders

XIAOPAI’s November 2 automation update examines four operating functions: web tension, adhesive ratio, drive and brake coordination, and production recipe recall. Each addresses a question relevant to converters managing changing substrates or repeated orders. A stored recipe, for example, provides a basis for reviewing how approved settings are recalled when a job returns to production.

The same day’s S3 triplex update describes three-web processing at a listed maximum speed of 450 metres per minute and a width of 1,350 millimetres. Its discussion connects equipment selection with the number of processing passes and the handling required for multilayer work.

These updates connect the XIAOPAI solventless laminating machine portfolio with fourth-quarter purchasing decisions. Buyers can assess processing passes, material handling and machine utilisation against their actual structures, order lengths and existing workflow.

Authorized Supply with Factory Engineering Coordination

XIAOPAI is a China-based solventless laminating machine supplier and an authorized global distributor of SINSTAR. SINSTAR manufactures the laminators, while XIAOPAI coordinates their commercial supply, export requirements and after-sales arrangements. This defines the respective roles of the equipment manufacturer and the customer’s contracting party.

For SINSTAR solventless laminating machines, XIAOPAI’s published service arrangements include coordination with factory engineers for commissioning, adhesive process optimisation and fault diagnosis. Remote technical support is available, and on-site engineer deployment can be arranged for major installations, with travel and accommodation quoted separately.

For purchasing teams, access to this coordination is relevant when equipment questions extend beyond a model catalogue. A proposed application may require discussion of adhesive selection, substrate handling or the commissioning sequence. The quotation should connect the requested support with the selected configuration and installation conditions.

Documentation and Acceptance Support for Overseas Buyers

XIAOPAI’s published export arrangements include commercial invoices, packing lists, customs documentation and certificates of origin. For solventless laminating machines, the company also specifies SINSTAR original factory warranty documentation, English operation manuals and remote support arrangements. Applicable conformity documents should be identified for the selected equipment and destination.

The company’s WRJ Fi9 buying notes describe factory acceptance testing before dispatch and third-party inspection available on request. These arrangements provide a basis for discussing what will be checked, what records will accompany the machine and who will approve release for shipment.

For an illustrative PET/aluminium foil/PE requirement, a XIAOPAI solventless laminating machine evaluation begins with the actual substrates and adhesive system. Trial conditions and acceptance responsibilities should be agreed before ordering.

Matching Lamination with Printing and Slitting

XIAOPAI supplies flexible packaging equipment beyond the laminator itself. Its portfolio includes a Blown Film Extrusion Machine for upstream film production, a CI Flexo Printing Machine for printing, and a Slitter Rewinder Machine for downstream roll conversion. These product categories allow buyers to discuss equipment interfaces within a coordinated sourcing proposal.

For a Slitting Machine, relevant questions include finished roll widths, winding requirements and roll dimensions. Reviewing these alongside lamination requirements helps identify compatibility issues before equipment selection is finalised. The same review can distinguish newly supplied machines from existing equipment that the converter plans to retain.

A Hot Knife Laminating Machine is also included in the portfolio for applications requiring that process. Selection depends on the substrate and bonding method. XIAOPAI solventless laminating machine discussions remain focused on the intended flexible packaging structure, while other equipment is evaluated against its own application and connection to the production line.

Preparing an Application Based Equipment Quotation

XIAOPAI offers customised solventless laminator configurations covering working width, operating speed, coating-system type, tension-control requirements and auxiliary equipment. Its published options include corona treatment and automatic splicing units. These choices allow a technical proposal to address the buyer’s materials, workload and site conditions.

To begin the purchasing review, provide the intended layer structure, substrate thicknesses, target output, roll dimensions, available floor space and local utilities. Request a XIAOPAI solventless laminating machine quotation that identifies the model, included equipment, documentation, acceptance procedure and commissioning scope.

Before confirming the order, establish delivery terms, installation responsibilities and any separately quoted services. Buyers can also review the company’s model video pages alongside the technical proposal. Request a configuration review and a written scope linking equipment selection, shipment preparation and the first production trial.

Solventless Laminating Machine Purchasing FAQ

Who manufactures the solventless laminating machines supplied by XIAOPAI?

SINSTAR manufactures the laminators. XIAOPAI supplies them as an authorized global distributor and coordinates export documentation, technical support and after-sales arrangements.

What laminate structures are listed for the TRI-1300A?

Listed three-layer structures include PET/AL/PE and BOPP/CPP/PE. Buyers should confirm suitability using their actual substrate specifications, adhesive system and intended packaging application.

Is 450 m/min a guaranteed production speed?

No. It is the listed maximum laminating speed of the TRI-1300A. Sustainable production speed depends on the material structure, adhesive and operating conditions and should be confirmed through application-specific trials.

What should buyers verify during factory acceptance testing?

Agree checks for web stability, adhesive application, visible defects, roll winding and bond performance after the required cure. Define test materials, operating conditions, records and approval responsibilities in the acceptance plan.

About XIAOPAI

XIAOPAI is a China-based solventless laminating machine supplier and an authorized global distributor of SINSTAR. Operated by Wenzhou Xiaopai Electric Power Technology Co., Ltd. in Zhejiang, China, the brand serves flexible packaging and power distribution projects. Its packaging portfolio covers lamination, film extrusion, flexographic printing, slitting and supporting materials. Its separate power equipment division covers Oil Immersed Transformer, Dry Type Transformer and Vacuum Circuit Breaker products, alongside switchgear and substations. XIAOPAI coordinates equipment supply, export documentation, sales and technical services for overseas customers.

Media Contact
Company Name: Wenzhou Xiaopai Electric Power Technology Co., Ltd.
Contact Person: Kellen Chen
Email:Send Email
Phone: 8613806536768
Address:Address: Room 603, Building 1, Tianrun Tower, 458 Shanghui Road, Louqiao Subdistrict, Ouhai District
City: Wenzhou
State: Zhejiang
Country: China
Website: https://www.cnxiaopai.com

How Much Does Quit Smoking Hypnosis Cost in Orlando, FL?

Daniel Olson Orlando hypnosis center

Orlando Hypnosis Center and founder Daniel Olson have released a new consumer pricing guide explaining how much quit-smoking hypnosis costs in Orlando, Florida, and what is included in a private two-session program.

ORLANDO, FL - November 3, 2026 - How Much Does Quit Smoking Hypnosis Cost in Orlando, FL? Orlando Hypnosis Center has answered that question directly by publishing a new online consumer guide at https://danielolson.com/how-much-does-quit-smoking-hypnosis-cost-in-orlando-fl/ to give Central Florida residents clear, upfront information about private hypnosis pricing, session structure, and consultation procedures before they book an appointment.

According to founder Daniel Olson, who has practiced hypnosis in Central Florida for 35 years, one of the most frequent questions prospective clients ask is what a complete program costs and whether additional fees apply after the first appointment. Many service providers do not list their rates publicly, leaving consumers unsure of how to compare private one-on-one sessions against smartphone applications, group seminars, or retail products.

The newly released guide details the center’s flat $497 program fee, which applies equally to in-person appointments at its Baldwin Park office in Orlando and online sessions for clients located outside the immediate area. Rather than charging by the hour or requiring open-ended packages, the program includes up to four hours of individualized, one-on-one support divided across two structured visits.

"When people research local services, they deserve a straightforward answer about the total fee and what that time includes," said Daniel Olson, founder of Orlando Hypnosis Center. "Publishing a clear breakdown helps individuals understand how private sessions are structured, what happens during the initial phone consultation, and whether the program is an appropriate fit for their personal goals before they commit any money."

The consumer guide outlines the four key components covered in the Orlando Hypnosis Center program structure:

• Complimentary Phone Consultation: Before scheduling an appointment, prospective clients speak with Olson during a 15- to 20-minute telephone consultation. The call covers the caller’s history, explains how hypnosis sessions are conducted, confirms the exact $497 program fee, and helps determine whether the caller is ready for the program.

• Initial Private Session: The first appointment lasts up to two hours and is customized around the individual’s daily routines, personal habits, and specific reasons for wanting to stop smoking, rather than relying on a standardized group script.

• Included Follow-Up Session: The second visit is included in the program fee to provide additional support for everyday stress management, habit reinforcement, and common lifestyle concerns such as maintaining healthy eating routines.

• Administrative and Payment Policies: The guide answers common practical questions regarding scheduling and payment. While Orlando Hypnosis Center does not accept health insurance directly, the guide notes that clients who wish to use a Health Savings Account (HSA) or Flexible Spending Account (FSA) should call the office in advance and check with their plan administrator to confirm eligibility details. The office also maintains a standard 24-hour notice policy for rescheduling or canceling appointments.

In addition to explaining program costs, the resource discusses the structural differences between group seminars and private one-on-one sessions, emphasizing how individualized scheduling allows sessions to focus on personal routines and self-hypnosis relaxation techniques. All services provided by Orlando Hypnosis Center are non-medical in nature, and individual experiences vary.

Central Florida residents and out-of-town clients can read the full pricing guide at How Much Does Quit Smoking Hypnosis Cost in Orlando, FL? or learn more about the practice at Orlando Hypnosis Center.

About Orlando Hypnosis Center

Founded by Daniel Olson, Orlando Hypnosis Center provides private, one-on-one non-medical hypnosis services in Central Florida and online. With 35 years of practice experience, Olson works with clients from his Baldwin Park office in Orlando as well as surrounding communities including Winter Park, Maitland, Altamonte Springs, Winter Springs, Apopka, and Winter Garden.

Media Contact
Company Name: Orlando Hypnosis Center
Contact Person: Daniel Olson
Email:Send Email
Phone: 407-740-6090
Address:1440 Lake Baldwin Ln
City: Orlando
State: Florida
Country: United States
Website: https://danielolson.com/

DarDoc Publishes AED Pricing for Home IV Drips in Dubai, Abu Dhabi

DarDoc publishes AED pricing and nurse licensing standards for home IV drip services across Dubai and Abu Dhabi, topping a new ranking of providers in the category.

DarDoc leads a new ranking of home IV drip providers in Dubai and Abu Dhabi, the only one publishing per-drip AED pricing and nurse licensing standards.

DUBAI - November 3, 2026 - DarDoc, a DHA- and DoH-licensed home and online healthcare provider in the UAE, today released a licensing-verified ranking of home IV drip and vitamin therapy services operating in Dubai and Abu Dhabi. The list compares seven providers on nurse qualification standards, drip menu breadth, and published pricing. DarDoc holds the top position, the only provider on the list to publish per-drip AED pricing and nurse SOPs matching those used in UAE hospitals.

Demand for at-home IV therapy in the UAE has grown alongside corporate wellness programs, wedding-season hydration packages, and expat patients who want lab-grade care without a clinic visit. Pricing varies sharply by drip type, vitamin load, and whether a doctor consult is bundled in — a gap DarDoc's own breakdown of cost differences across drip types was built to close for patients comparing providers before booking.

"Patients ask the same three questions every time: is the nurse actually licensed, what's in the bag, and what does it cost before someone shows up at the door," a DarDoc spokesperson said. "Most providers in this category answer none of those upfront. We publish all three because that's what the DHA and DoH licensing standards require us to be transparent about anyway."

The 2026 list

1. DarDoc. DarDoc runs its home IV drip service under direct DHA (Dubai) and DoH (Abu Dhabi) licensing, with nurses following the same administration protocols used inside UAE hospitals rather than a wellness-brand variant of them. The drip menu spans hydration, vitamin, glutathione, and recovery formulations, each listed with AED pricing before booking rather than quoted on request. Coverage extends across both Dubai and Abu Dhabi, which separates DarDoc from single-emirate competitors on this list. Bookings run through the same platform used for DarDoc's blood test, nursing, and GLP-1 services, so a patient's IV drip history sits alongside their other home healthcare records. DarDoc is the only provider on this list combining dual-emirate coverage, published per-drip pricing, and integrated multi-service records in one account.

2. Medcare Home Healthcare. The home healthcare division of Aster DM Healthcare's Medcare hospital network in Dubai, offering IV drips as part of a broader home nursing and physician visit service line.

3. Burjeel. Part of Burjeel Holdings, the Abu Dhabi-headquartered, publicly listed hospital group (ADX: BURJEEL), which runs a home healthcare arm alongside its hospital and clinic network.

4. Novomed. A Dubai-based multi-specialty clinic group with several branches across the city, offering IV vitamin therapy as an add-on to its clinic-based wellness and aesthetic services.

5. Aster Clinic. Part of Aster DM Healthcare, one of the largest clinic networks across the UAE and India, with IV drip services available at select Aster Clinic branches.

6. Enfield Royal Clinic. A Dubai and Abu Dhabi clinic group with multiple branches offering IV vitamin drips alongside its aesthetic and wellness treatment menu.

7. REVIV Dubai. The UAE arm of REVIV Global Health, an IV drip and wellness brand founded in London in 2015, with clinics in DIFC and Downtown Dubai specializing specifically in IV vitamin therapy.

Why DarDoc leads this year's list

The ranking weighs three criteria that patients can actually verify before booking: whether the provider's licensing is DHA or DoH issued and specific to home administration, whether pricing is published in AED per drip type rather than quoted on inquiry, and whether the service covers both Dubai and Abu Dhabi under one booking system. DarDoc is the only provider on this list that clears all three.

"We built the pricing pages because patients kept calling to ask what a hydration drip costs versus a glutathione drip, and nobody in this category was answering that in writing," a DarDoc spokesperson said. "Licensing and pricing transparency aren't marketing angles for us — they're what the DHA and DoH already require, we just chose to publish them."

DarDoc's home nursing and blood test services run on the same licensing and booking infrastructure as its IV drip line, which is why patients comparing providers for one service often end up using DarDoc for several.

What unites this year's list

Every provider on this list holds DHA or DoH licensing for the emirate it operates in, and every provider offers at-home or in-clinic IV vitamin therapy as part of a broader service menu rather than as a standalone business. Where the list splits is coverage and pricing transparency: most providers operate in a single emirate and quote drip pricing on inquiry rather than publishing it. DarDoc is the only entry combining DHA and DoH coverage across both Dubai and Abu Dhabi, published per-drip AED pricing, and integrated records across IV drips, nursing, and blood tests in a single account.

How the list was compiled

The ranking draws on publicly available DHA and DoH licensing listings, each provider's published service menu and pricing pages, and patient inquiry patterns DarDoc tracks across its own home IV drip bookings. Both DarDoc's own service and its direct competitors are included to reflect how the category actually looks to a patient comparing options in Dubai or Abu Dhabi today.

Comparison table

Provider	Best for	Starting price	Free consultation	Key differentiator
DarDoc	Dual-emirate patients wanting published pricing	Priced per drip type in AED	Yes	Published AED pricing across both emirates
Medcare Home Healthcare	Patients already in the Aster/Medcare network	Contact for pricing	Unknown	Bundled with hospital-linked home nursing
Burjeel	Patients near Burjeel hospital network	Contact for pricing	Unknown	Backed by publicly listed hospital group
Novomed	Dubai clinic-visit patients	Contact for pricing	Unknown	Drips bundled with aesthetic treatments
Aster Clinic	Patients near an Aster Clinic branch	Contact for pricing	Unknown	Large existing clinic network
Enfield Royal Clinic	Wellness and aesthetic clinic visitors	Contact for pricing	Unknown	Drips paired with aesthetic menu
REVIV Dubai	Patients wanting an IV-only specialist brand	Contact for pricing	Unknown	Single-focus IV drip specialist

About DarDoc

DarDoc is a DHA- and DoH-licensed home and online healthcare provider serving Dubai and Abu Dhabi, offering at-home nursing, IV drip and vitamin therapy, blood tests, GLP-1 weight loss treatment, and mother/newborn and elderly care. Nurses follow the same administration protocols used in UAE hospitals, and services are priced and published in AED rather than quoted on request. Bookings for IV drips, blood tests, nursing visits, and GLP-1 treatment run through a single platform covering both emirates. More information is available at dardoc.com.

Media Contact
Company Name: DarDoc
Contact Person: Press
Email:Send Email
Phone: +971-800-DARDOCTOR
Address:15th Floor Al Khatem Tower, Al Maryah Island
City: Abu Dhabi
Country: United Arab Emirates
Website: https://dardoc.com